Similar articles

• Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.

  Stout JE. Stout JE. Expert Opin Drug Saf. 2004 May;3(3):187-98. doi: 10.1517/eods.3.3.187.31073. Expert Opin Drug Saf. 2004. PMID: 15155147 Review.
• Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.

  Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, Barry MA, O'Brien RJ. Gordin F, et al. JAMA. 2000 Mar 15;283(11):1445-50. doi: 10.1001/jama.283.11.1445. JAMA. 2000. PMID: 10732934 Clinical Trial.
• Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.

  Jasmer RM, Snyder DC, Saukkonen JJ, Hopewell PC, Bernardo J, King MD, Kawamura LM, Daley CL; Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection Study Investigators. Jasmer RM, et al. Clin Infect Dis. 2004 Feb 1;38(3):363-9. doi: 10.1086/380966. Epub 2004 Jan 13. Clin Infect Dis. 2004. PMID: 14727206 Clinical Trial.
• Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.

  Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, Baruch N, Adelakun A, Dorman SE. Page KR, et al. Arch Intern Med. 2006 Sep 25;166(17):1863-70. doi: 10.1001/archinte.166.17.1863. Arch Intern Med. 2006. PMID: 17000943
• Treatment of latent tuberculosis infection.

  Vernon A. Vernon A. Semin Respir Crit Care Med. 2013 Feb;34(1):67-86. doi: 10.1055/s-0032-1333544. Epub 2013 Mar 4. Semin Respir Crit Care Med. 2013. PMID: 23460007 Review.